Pharmaceutical - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

76 to 100 of 253 results

Johnson & Johnson to pay over $2.2 billion to settle DoJ probe

Johnson & Johnson to pay over $2.2 billion to settle DoJ probe

05-11-2013

Global health care giant Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve…

FinancialInvegaJanssenJohnson & JohnsonLegalMarkets & MarketingNatrecorNorth AmericaPharmaceuticalRisperdalScios

AHF sues Johnson & Johnson over AIDS drug pricing

AHF sues Johnson & Johnson over AIDS drug pricing

01-11-2013

The Washington DC, USA-based AIDS Healthcare Foundation (AHF) has filed a law suit in the Superior Court…

Anti-viralsJanssenJohnson & JohnsonLegalNorth AmericaPharmaceuticalPricing

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

25-10-2013

Janssen announced yesterday that the FDA's Antiviral Drugs Advisory Committee unanimously recommended…

Anti-viralsJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevir

Janssen-Cilag files European approval of combination medicine for HIV-1

16-10-2013

US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

Johnson & Johnson third quarter beats analysts’ forecasts boosted by new Rx drugs

Johnson & Johnson third quarter beats analysts’ forecasts boosted by new Rx drugs

16-10-2013

Johnson & Johnson kicked off the third-quarter 2013 pharma financial results reporting period, posting…

FinancialJohnson & JohnsonPharmaceutical

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

11-10-2013

Anglo-Swedish drug major AstraZeneca has entered into an agreement with US health care giant Johnson…

abirateroneAsia-PacificAstraZenecaJanssenJohnson & JohnsonLicensingMarkets & MarketingOncologyPharmaceuticalZytiga

Janssen gains rights to Ph II hepatitis C candidate from GSK

08-10-2013

Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Johnson & Johnson enters novel collaborations in Europe

Johnson & Johnson enters novel collaborations in Europe

04-10-2013

Johnson & Johnson Innovation, a branch of US pharma giant Johnson & Johnson, has announced several new…

EuropeJanssen BiotechJohnson & JohnsonOncologyPharmaceuticalResearch

UK’s NICE issues draft guidance on suite of ovarian cancer drugs

27-09-2013

Drugs watchdog the National Institute for Health and Care Excellence (NICE) is currently considering…

Europegemcitabine HclGlaxoSmithKlineJohnson & JohnsonLillyOncologyPharmaceuticalPricingRegulationtrabectedin

Prostate cancer market set to grow 50% by 2021: report

06-09-2013

The increasing number of sufferers and the uptake of new drugs will see the prostate cancer market grow…

Asia-PacificAstellas PharmaEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalXtandiZytiga

Janssen files for simultaneous US and EU approval for Castleman disease drug

04-09-2013

Janssen Research & Development, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), yesterday…

EuropeJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRare diseasesRegulationsiltuximab

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report

30-08-2013

German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

FDA acceptance of ibrutinib NDA triggers milestone for Pharmacyclics

30-08-2013

California, USA-based Pharmacyclics (Nasdaq: PCYC) said yesterday (August 29, 2013) that the US Food…

BiotechnologyibrutinibJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

Study of mechanism of ibrutinib action in mantle cell lymphoma

22-08-2013

A study that investigated the mechanism of ibrutinib's anti-tumor effect in patients with mantle cell…

ibrutinibJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Mitsubishi Tanabe succeeds in arbitration

11-08-2013

Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) says it has been awarded $117 million in an…

Anti-Arthritics/RheumaticsAsia-PacificJanssen BiotechJohnson & JohnsonLicensingMitsubishi TanabePharmaceuticalPricingRemicade

EU backs wider use of Velcade

09-08-2013

The European Commission has approved the use of Johnson & Johnson (NYSE: JNJ) European subsidiary Janssen-Cilag's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

Simponi ARIA cleared by US FDA

19-07-2013

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Biotech subsidiary has received US Food…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi ARIA

Johnson & Johnson 2nd-qtr beats expectations

17-07-2013

US health care giant Johnson & Johnson (NYSE: JNJ) reported second quarter 2013 earnings of $3.83 billion,…

FinancialJohnson & JohnsonPharmaceutical

Janssen submits NDA for "breakthrough" leukemia and lymphoma drug ibrutinib

11-07-2013

Janssen Pharmaceuticals, a unit of US health care giant Johnson & Johnson (NYSE: JNJ), has submitted…

ibrutinibJanssen PharmaceuticaJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

76 to 100 of 253 results

Back to top